首页> 外文期刊>World Journal of Gastroenterology >Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro.
【24h】

Antibody to E1 peptide of hepatitis C virus genotype 4 inhibits virus binding and entry to HepG2 cells in vitro.

机译:丙型肝炎病毒基因型4的E1肽抗体在体外抑制病毒结合和进入HepG2细胞。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To analyze the neutralizing activity of antibodies against E1 region of hepatitis C virus (HCV). Specific polyclonal antibody was raised via immunization of New Zealand rabbits with a synthetic peptide that had been derived from the E1 region of HCV and was shown to be highly conserved among HCV published genotypes. METHODS: Hyper-immune HCV E1 antibodies were incubated over night at 4 degree Celsius with serum samples positive for HCV RNA, with viral loads ranging from 615 to 3.2 million IU/ mL. Treated sera were incubated with HepG2 cells for 90 min. Blocking of viral binding and entry into cells by anti E1 antibody were tested by means of RT-PCR and flow cytometry. RESULTS: Direct immunostaining using FITC conjugated E1 antibody followed by Flow cytometric analysis showed reduced mean fluorescence intensity in samples pre-incubated with E1 antibody compared with untreated samples. Furthermore, 13 out of 18 positive sera (72%) showed complete inhibition of infectivity as detected by RT-PCR. CONCLUSION: In house produced E1 antibody, blocks binding and entry of HCV virion infection to target cells suggesting the involvement of this epitope in virus binding and entry. Isolation of these antibodies that block virus attachment to human cells are useful as therapeutic reagents.
机译:目的:分析抗丙型肝炎病毒(HCV)E1区抗体的中和活性。通过用合成肽免疫新西兰兔来产生特异性多克隆抗体,该合成肽源于HCV E1区,并且在HCV发表的基因型中被证明是高度保守的。方法:将高免疫力的HCV E1抗体与4摄氏度的HCV RNA阳性血清样品一起孵育过夜,病毒载量范围为615至320万IU / mL。将处理过的血清与HepG2细胞孵育90分钟。通过RT-PCR和流式细胞术检测抗E1抗体对病毒结合的阻断和进入细胞。结果:使用FITC偶联的E1抗体进行直接免疫染色,然后进行流式细胞术分析,与未处理的样品相比,用E1抗体预孵育的样品的平均荧光强度降低。此外,通过RT-PCR检测到,在18份阳性血清中有13份(72%)显示出完全抑制了感染性。结论:内部产生的E1抗体可阻止HCV病毒粒子与靶细胞的结合和进入,提示该表位与病毒的结合和进入有关。阻断病毒附着于人细胞的这些抗体的分离可用作治疗剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号